PTC Therapeutics (PTCT) News Today

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) have climbed recently amid a flurry of analyst actions. While some firms are adding the stock to focus lists and keeping high price objectives, others are trimming earnings forecasts and cutting targets. Investors should weigh the bullish signals—like conference appearances and “Overweight” ratings—against the headwinds of lower EPS projections and reduced price targets.

• Positive Sentiment: Cantor Fitzgerald maintains an “Overweight” rating on PTCT with a $120.00 price objective, underscoring confidence in the company’s long-term prospects.
• Positive Sentiment: JPMorgan adds PTCT to its Analyst Focus List after a recent selloff Article Title
• Positive Sentiment: PTC Therapeutics to participate at upcoming investor conferences, including the Cantor Global Healthcare Conference Article Title
• Neutral Sentiment: The stock rallied 7.6% in recent trading as investors sought entry points; analysts debate whether the move is a buying opportunity Article Title
• Negative Sentiment: Bank of America cuts its PTCT price target from $82.00 to $76.00, though it maintains a “Buy” rating Article Title
• Negative Sentiment: Cantor Fitzgerald lowers its FY2026 EPS estimate for PTCT to ($6.71) from ($6.57), widening the gap to the consensus of ($4.52) per share.
• Negative Sentiment: William Blair slashes multiple quarterly and full-year EPS forecasts—cutting FY2026 to ($2.90) from ($1.88) and lowering Q4 2025-Q3 2026 estimates across the board Article Title
• Negative Sentiment: Morgan Stanley trims its PTCT price target to $71.00 Article Title
• Negative Sentiment: Wells Fargo cuts its PTCT price target to $73.00 Article Title
• Negative Sentiment: Bank of America issues a pessimistic forecast for PTCT’s stock performance Article Title